Trial Profile
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2018
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- 13 Sep 2017 Status changed from not yet recruiting to discontinued.
- 23 Aug 2014 New trial record